Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06132958 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06132958 · ClinicalTrials.gov record · last posted 2026-04-03

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Study acronym: TroFuse-005
StatusActive, Not Recruiting
PhasePhase 3
Started2023-12-06
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.

Amendment record 61 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 61 times since 2023-11-10; most recent amendment 2026-03-30. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-09-26
Status change Recruiting→Active, Not Recruitingv55
2023-12-12
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06132958
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Conditions Endometrial Cancer
Enrollment 710 participants
Start Date 2023-12-06
Primary Completion 2028-01-10 (estimated)
Study Completion 2028-01-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-03